Benzinga

Benzinga

Benzinga

venerdì, agosto 28

Viking Therapeutics Inc

VKTXNASDAQ
Trade with Public
Trade with Public
$33.41
-0.45-1.33%
Ult. Agg.: Aug 28, 9:34 AM
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Viking Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viking Therapeutics (VKTX).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

1S.Buy
14Buy
2Hold
Consensus RatingBuy# Analysts17Avg. Consensus PT$94Upside to Avg. PT+182.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2026JP MorganHardik ParikhPT CutOverweight$75→$65
Jul 30, 2026Canaccord GenuityEdward NashPT RaiseBuy$107→$114
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $75 to $65.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $114

Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $107 to $114.
Benzinga Newsdesk

PRO
Lake Street Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $89

Lake Street analyst Daniel Brims initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $89.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Viking Therapeutics, Lowers Price Target to $100

Cantor Fitzgerald analyst Steve Seedhouse maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $105 to $100.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $102 price target.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Viking Therapeutics, Raises Price Target to $107

Canaccord Genuity analyst Edward Nash maintains Viking Therapeutics (NASDAQ:VKTX) with a Buy and raises the price target from $106 to $107.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved